{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:34:24Z","timestamp":1780623264695,"version":"3.54.1"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Venetoclax plus 3\u00a0+\u00a07 daunorubicin and cytarabine chemotherapy (DAV) has shown safety and efficacy in eligible patients with newly diagnosed acute myeloid leukemia (AML). However, there are no direct comparisons between DAV and 3\u00a0+\u00a07 daunorubicin and cytarabine chemotherapy (DA) alone. We performed a propensity score\u2010matched analysis to compare the outcomes of DAV group with historical DA group and identify the clinical and molecular characteristics of patients who might benefit from the DAV regimen. The DAV group had a higher Complete remission (CR) rate than the DA group (90% vs. 55%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.008). 25 (96%) patients in the DAV group had a higher MRD\u2010negative CRc rate compared with 13 (62%) patients in the DA group (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.006). After a median follow\u2010up duration of 19.15 (IQR 17.13\u201321.67) months, the DAV group had an improved overall survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.001) and event\u2010free survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.069), but not disease\u2010free survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.136). Collectively, DAV regimen induced high CR rates and deep MRD\u2010negative CRc rates after one cycle of induction therapy, as well as prolonged the overall survival, in young adult patients with AML who were eligible for intensive chemotherapy. The addition of venetoclax to intensive chemotherapy should be considered in the future to achieve better survival advantages in eligible AML patients.\n                  <\/jats:p>","DOI":"10.1002\/hon.3260","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T07:06:02Z","timestamp":1709103962000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score\u2010matched analysis"],"prefix":"10.1002","volume":"42","author":[{"given":"Rong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-2288","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8360-6395","authenticated-orcid":false,"given":"Huafeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinjun","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaixiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-5581","authenticated-orcid":false,"given":"Wanzhuo","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juying","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4553-2751","authenticated-orcid":false,"given":"Xiujin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-9915","authenticated-orcid":false,"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-0436","authenticated-orcid":false,"given":"Hong\u2010Hu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang China"},{"name":"Zhejiang University Cancer Center  Hangzhou Zhejiang China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders  Hangzhou Zhejiang China"},{"name":"Liangzhu Laboratory Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"4","key":"e_1_2_9_2_1","first-page":"485","article-title":"Cytosine arabinoside (NSC\u201063878) and daunorubicin (NSC\u201083142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates JW","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0904544"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.47.4874"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23884"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.72.8618"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(12)60485\u20101"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.187"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26043"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33690"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201008\u2010868752"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01600"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2012971"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00572"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03736"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(21)00192\u20107"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(22)00106\u20105"},{"issue":"3","key":"e_1_2_9_19_1","first-page":"177","article-title":". [Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017)]","volume":"38","author":"Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association","year":"2017","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"issue":"12","key":"e_1_2_9_20_1","first-page":"1001","article-title":".\u00a0[Expert consensus on minimal residual disease detection of acute leukemia and plasma cell neoplasms by multi\u2010parameter flow cytometry]","volume":"38","author":"Chinese Society of Immunology, Clinical Flow Cytometry Group","year":"2017","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12350\u2010017\u20101012\u2010y"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(22)00076\u2010x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201008\u2010733196"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4600"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1716863"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.10.005"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100233\u20101"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009081"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.37.1286"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T04:35:19Z","timestamp":1758688519000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/hon.3260"],"URL":"https:\/\/doi.org\/10.1002\/hon.3260","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.3260\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3260\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3260\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3260\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3260\/v2\/review1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"2023-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3260"}}